Anika Therapeutics Enrolls First Patient in U.S. Clinical Study for Monovisc™

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has enrolled the first patient in a multi-center study evaluating its single-injection osteoarthritis product, MONOVISC™.